STOCK TITAN

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), will have its president and CEO, Douglas Love, participate in a fireside chat during the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023. The company is developing complement-based medicines for inflammatory-related diseases. A live webcast of the event will be available on the Investors page at www.annexonbio.com, with a replay archived for 30 days.
Positive
  • None.
Negative
  • None.

BRISBANE, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at 2:10 p.m. ET in Miami.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company utilizing a distinct scientific approach to stop C1q and all inflammatory aspects of classical complement pathway activation before it starts. As the only company solely focused on shutting down C1q, Annexon is developing a fit-for-purpose pipeline of therapeutics designed to provide meaningful benefits across multiple diseases of the body, brain and eye. With proof-of concept data in both Guillain-Barré syndrome and geographic atrophy, Annexon is rigorously advancing its mid-to late-stage clinical trials to bring their potential treatments to patients as quickly as possible. To learn more visit annexonbio.com.

Investor Contact:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media Contact:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com


FAQ

What is Annexon, Inc.'s ticker symbol?

The ticker symbol for Annexon, Inc. is ANNX.

When will Douglas Love participate in the fireside chat?

Douglas Love will participate in the fireside chat on November 29, 2023.

What type of medicines is Annexon, Inc. developing?

Annexon, Inc. is developing a new class of complement-based medicines for inflammatory-related diseases.

Where can I access the live webcast of the event?

The live webcast of the event can be accessed on the Investors page at www.annexonbio.com.

How long will the replay of the webcast be available?

The replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

Annexon, Inc.

NASDAQ:ANNX

ANNX Rankings

ANNX Latest News

ANNX Stock Data

553.22M
98.66M
0.5%
106.1%
7.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRISBANE